A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912199" target="_blank" >RIV/00216208:11120/17:43912199 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/17:N0000024

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ejh.12807" target="_blank" >http://dx.doi.org/10.1111/ejh.12807</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.12807" target="_blank" >10.1111/ejh.12807</a>

Jazyk výsledku

angličtina

Název v původním jazyce

A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice

Popis výsledku v původním jazyce

OBJECTIVE: Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 years in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in European clinical practice. METHODS: Adults with primary ITP who received romiplostim in routine care were eligible. RESULTS: Three-hundred and forty patients were eligible for analysis, of whom 299 (88%) completed the two-year observation period. The median age was 62 years, with 43% of patients aged GREATER-THAN OR EQUAL TO65 years, and two-thirds of patients initiated romiplostim before splenectomy. The median average weekly dose of romiplostim was 2.8 μg/kg. The median baseline platelet count was 20 x 10(9) /L, which increased after 2 weeks of romiplostim treatment and remained &gt;50 x 10(9) /L thereafter. After romiplostim initiation, there was a decrease in rates of grade GREATER-THAN OR EQUAL TO3 bleeding events (from 12 to 2 per 100 patient-years) and ITP-related hospitalisations (from 87 to 33 per 100 patient-years). The rate of thrombotic events was 2 per 100 patient-years and bone marrow fibrosis occurred in two patients. CONCLUSIONS: Romiplostim dosing, effectiveness, and safety in an unselected real-world ITP population seemed comparable with that observed in clinical studies.

Název v anglickém jazyce

A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice

Popis výsledku anglicky

OBJECTIVE: Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 years in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in European clinical practice. METHODS: Adults with primary ITP who received romiplostim in routine care were eligible. RESULTS: Three-hundred and forty patients were eligible for analysis, of whom 299 (88%) completed the two-year observation period. The median age was 62 years, with 43% of patients aged GREATER-THAN OR EQUAL TO65 years, and two-thirds of patients initiated romiplostim before splenectomy. The median average weekly dose of romiplostim was 2.8 μg/kg. The median baseline platelet count was 20 x 10(9) /L, which increased after 2 weeks of romiplostim treatment and remained &gt;50 x 10(9) /L thereafter. After romiplostim initiation, there was a decrease in rates of grade GREATER-THAN OR EQUAL TO3 bleeding events (from 12 to 2 per 100 patient-years) and ITP-related hospitalisations (from 87 to 33 per 100 patient-years). The rate of thrombotic events was 2 per 100 patient-years and bone marrow fibrosis occurred in two patients. CONCLUSIONS: Romiplostim dosing, effectiveness, and safety in an unselected real-world ITP population seemed comparable with that observed in clinical studies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Svazek periodika

98

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

112-120

Kód UT WoS článku

000393167400002

EID výsledku v databázi Scopus

2-s2.0-84994344530